The inclusion of therapeutic monoclonal antibodies (mAbs) in treatment regimens for multiple myeloma provides patients with significant improvements in clinical outcomes. Daratumumab and isatuximab are human mAbs targeting CD38, used in multiple myeloma treatment protocols.
HYDRASHIFT prevents therapeutic mAb interference in the interpretation of immunofixation tests.
HYDRASHIFT is an immunofixation procedure performed on HYDRAGEL IF 2/4 gel and is based on the formation of an immune complex between the therapeutic mAb and its specific anti-mAb antibody, causing the complex to shift out of the gamma-globulin zone.
In the HYDRASHIFT technique, this complex is visualized in the alpha-1 region on the IgG and Kappa immunofixation tracks.
A negative HYDRASHIFT result confirms the absence of an endogenous M-protein.
Serum
Sensitivity
The detection limit of the visualized immune complex is 0.3 g/L.
HYDRASHIFT 2/4 daratumumab (20 tests) – Ref.: 4639
Daratumumab control – Ref.: 4765
HYDRASHIFT 2/4 isatuximab (40 tests) – Ref.: 4642
Isatuximab control – Ref.: 4764
Yüksek çözünürlüklü sonuçlarla yüksek verimli Serum Protein Elektroforezi.
Ödün Verilmemiş HbA1c Sonuçları.
Hemoglobin bozukluklarının taranmasında yüksek çözünürlüklü yöntem.
Yüksek çözünürlüklü sonuçlarla yüksek verimli Serum Protein Elektroforezi.
Yüksek çözünürlüklü sonuçlarla yüksek verimli Serum Protein Elektroforezi.
Yüksek çözünürlüklü sonuçlarla yüksek verimli Serum Protein Elektroforezi.
